相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer
M. R. Boland et al.
BRITISH JOURNAL OF SURGERY (2020)
Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma
Hyun-Soo Kim et al.
ANTICANCER RESEARCH (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer
Wang Xinran et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer
Tomoko Hirakata et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer
Lijuan Wei et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old
Zoi Evangelou et al.
IN VIVO (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Intratumoral, rather than stromal, CD8+T cells could be a potential negative prognostic marker in invasive breast cancer patients
Ivana Catacchio et al.
TRANSLATIONAL ONCOLOGY (2019)
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
Yan Li et al.
FRONTIERS IN PHARMACOLOGY (2019)
Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer
Xudong Zhu et al.
CANCER BIOLOGY & THERAPY (2019)
Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer A systematic review and meta-analysis
Shichao Li et al.
MEDICINE (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
The predictive and prognostic value of Foxp3+/CD25+regulatory T cells and PD-L1 expression in triple negative breast cancer
Lin Zhang et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2019)
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis
Wenfa Huang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients
Dae-Won Lee et al.
BRITISH JOURNAL OF CANCER (2019)
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Alexios Matikas et al.
CLINICAL CANCER RESEARCH (2019)
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer
Jieun Lee et al.
CANCER RESEARCH AND TREATMENT (2019)
Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival
Timucin Erol et al.
MEDICINE (2019)
Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer
Yan Zeng et al.
ONCOTARGETS AND THERAPY (2019)
Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis
Lei Zhu et al.
FRONTIERS IN PHARMACOLOGY (2019)
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Sasagu Kurozumi et al.
SCIENTIFIC REPORTS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers
Yanjun Hou et al.
HUMAN PATHOLOGY (2019)
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
C. Van Berckelaer et al.
BREAST CANCER RESEARCH (2019)
Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
Sumi Yun et al.
JOURNAL OF CANCER (2019)
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients
Rabia Dogukan et al.
EUROPEAN JOURNAL OF BREAST HEALTH (2019)
Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
Thomas A. Adams et al.
MODERN PATHOLOGY (2018)
An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
Lauren E. McLemore et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications
Jing He et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
The combined presence of CD20+B cells and PD-L1+tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome
H. Arias-Pulido et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer
Xinyu Ren et al.
CANCER BIOLOGY & THERAPY (2018)
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
Yanjun Hou et al.
CLINICAL BREAST CANCER (2018)
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells
Ossama Tawfik et al.
HUMAN PATHOLOGY (2018)
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters
Fei Li et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2018)
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
Yuka Asano et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
Vasiliki Pelekanou et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
Tingting Zhou et al.
ANTI-CANCER DRUGS (2018)
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer
Yanjun Hou et al.
BREAST JOURNAL (2018)
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren et al.
CELL (2018)
Programmed Cell Death Protein-1 Predicts the Recurrence of Breast Cancer in Patients Subjected to Radiotherapy After Breast-Preserving Surgery
Ruyi Huang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms
Jianli Ma et al.
JOURNAL OF CANCER (2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite et al.
ONCOIMMUNOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
Mehmet Altan et al.
NPJ BREAST CANCER (2018)
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
NiJiati AiErken et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy
Sheng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
Gerardo Botti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
Antonio Polonia et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer
Sasagu Kurozumi et al.
MEDICAL MOLECULAR MORPHOLOGY (2017)
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast
Elizabeth D. Thompson et al.
MODERN PATHOLOGY (2017)
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
Hitomi Mori et al.
ONCOTARGET (2017)
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli et al.
BIOMED RESEARCH INTERNATIONAL (2017)
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schuetz et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
Jian Lou et al.
OPEN MEDICINE (2017)
Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer
Mina Okabe et al.
CANCER SCIENCE (2017)
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Vasiliki Pelekanou et al.
BREAST CANCER RESEARCH (2017)
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano et al.
ESMO OPEN (2017)
PD-L1 expression and tumor infiltrating PD-1+lymphocytes associated with outcome in HER2+breast cancer patients
Julia Y. S. Tsang et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer
Honggeng Guan et al.
ONCOIMMUNOLOGY (2016)
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Xiaoxian Li et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
In Hae Park et al.
CLINICAL BREAST CANCER (2016)
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K. Beckers et al.
HISTOPATHOLOGY (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista et al.
HUMAN PATHOLOGY (2016)
Expression of Programmed Death Receptor Ligand 1 with High Tumor Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
Sang Byung Bae et al.
JOURNAL OF BREAST CANCER (2016)
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Woo Young Sun et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
Lei Guo et al.
SPRINGERPLUS (2016)
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer
Nadine Tung et al.
NPJ BREAST CANCER (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
Tao Qin et al.
ONCOTARGET (2015)
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
Francois Bertucci et al.
ONCOTARGET (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Histologic Grade Remains a Prognostic Factor for Breast Cancer Regardless of the Number of Positive Lymph Nodes and Tumor Size A Study of 161 708 Cases of Breast Cancer From the SEER Program
Arnold M. Schwartz et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer
Piotr Tymoszuk et al.
BMC CANCER (2014)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
E. C. Inwald et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The hallmarks of cancer A long non-coding RNA point of view
Tony Gutschner et al.
RNA BIOLOGY (2012)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland
A. Spitale et al.
ANNALS OF ONCOLOGY (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells
Hazem Ghebeh et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Prognostic value of proliferation in invasive breast cancer: a review
PJ van Diest et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
